Metraipolis › archive › dc_272b68f28353
Nilotinib and imatinib: potential candidates for treatment of dementia and Parkinson's disease through national health insurance data — Europe PMC PMID:40937178
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40937178
- DOI
- 10.3389/fneur.2025.1628876
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T08:00:09.571Z
- SHA-256 of the archived text
222063e8017e34ecb43d162e358137faa1b442b751a73149e343c4144a302843- Stable URL of this page
https://metraipolis.com/documento/dc_272b68f28353
How to cite
Nilotinib and imatinib: potential candidates for treatment of dementia and Parkinson's disease through national health insurance data — Europe PMC PMID:40937178 — Europe PMC (en), https://europepmc.org/article/MED/40937178 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_272b68f28353 (Metraipolis archive dc_272b68f28353, sha256 222063e8017e34ecb43d162e358137faa1b442b751a73149e343c4144a302843)
BibTeX
@misc{dc272b68f28353,
title = {Nilotinib and imatinib: potential candidates for treatment of dementia and Parkinson's disease through national health insurance data — Europe PMC PMID:40937178},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40937178},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_272b68f28353; sha256 222063e8017e34ecb43d162e358137faa1b442b751a73149e343c4144a302843},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40937178. Agents can read the archived copy with the MCP tool read_document.